Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab Dose-finding Study in CSU
NCT02477332Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of ligelizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Jul 2015; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02477332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477332.